Shazli Azmi1,2, Maryam Ferdousi1, Yifen Liu1, Safwaan Adam1,3, Zohaib Iqbal1,4, Shaishav Dhage1,3, Georgios Ponirakis5, Tarza Siahmansur1, Andrew Marshall6, Ioannis Petropoulos5, Alise Kalteniece1, Jan Hoong Ho1,4, Akheel Syed7, John M Gibson7, Basil J Ammori1,8, Paul N Durrington1, Rayaz A Malik1,5, Handrean Soran9,10. 1. Division of Cardiovascular Sciences, School of Medical Sciences, Core Technology Facility, University of Manchester, Manchester, UK. 2. Manchester Diabetes Centre, Manchester University Foundation Trust, Manchester, UK. 3. The Christie NHS Foundation Trust, Manchester, UK. 4. Cardiovascular Trials Unit, Manchester University Hospitals, Manchester, UK. 5. Weill Cornell Medicine-Qatar, Doha, Qatar. 6. Institute of Life course and Medical Sciences, University of Liverpool, Liverpool, UK. 7. Department of Diabetes and Endocrinology, Salford Royal Trust NHS Foundation Trust, Salford, UK. 8. Department of Surgery, Salford Royal Trust NHS Foundation Trust, Salford, UK. 9. Division of Cardiovascular Sciences, School of Medical Sciences, Core Technology Facility, University of Manchester, Manchester, UK. hsoran@aol.com. 10. Cardiovascular Trials Unit, Manchester University Hospitals, Manchester, UK. hsoran@aol.com.
Abstract
INTRODUCTION: Subjects with obesity have metabolic risk factors for nerve fibre damage. Because bariatric surgery improves these risk factors we have assessed whether this can ameliorate nerve fibre damage. METHODS: Twenty-six obese subjects without diabetes (age: 46.23 ± 8.6, BMI: 48.7 ± 1.5, HbA1c: 38.0 ± 4.5) and 20 controls (age: 48.3 ± 6.2, BMI: 26.8 ± 4.2, HbA1c: 39.1 ± 2.6) underwent detailed assessment of neuropathy at baseline and 12 months after bariatric surgery. RESULTS: Obese subjects had normal peroneal (45.9 ± 5.5 vs. 48.1 ± 4.5, P = 0.1) and sural (46.9 ± 7.6 vs. 47.9 ± 10.6, P = 0.1) nerve conduction velocity, but a significantly higher neuropathy symptom profile (NSP) (4.3 ± 5.7 vs. 0.3 ± 0.6, P = 0.001), vibration perception threshold (VPT) (V) (10.2 ± 6.8 vs. 4.8 ± 2.7, P < 0.0001), warm threshold (C°) (40.4 ± 3.5 vs. 37.2 ± 1.8, P = 0.003) and lower peroneal (3.8 ± 2.2 vs. 4.9 ± 2.2, P = 0.02) and sural (8.9 ± 5.8 vs. 15.2 ± 8.5, P < 0.0001) nerve amplitude, deep breathing-heart rate variability (DB-HRV) (beats/min) (21.7 ± 4.1 vs. 30.1 ± 14, P = 0.001), corneal nerve fibre density (CNFD) (n/mm2) (25.6 ± 5.3 vs. 32.0 ± 3.1, P < 0.0001), corneal nerve branch density (CNBD) (n/mm2) (56.9 ± 27.5 vs. 111.4 ± 30.7, P < 0.0001) and corneal nerve fibre length (CNFL) (mm/mm2) (17.9 ± 4.1 vs. 29.8 ± 4.9, P < 0.0001) compared to controls at baseline. In control subjects there was no change in neuropathy measures over 12 months. However, 12 months after bariatric surgery there was a significant reduction in BMI (33.7 ± 1.7 vs. 48.7 ± 1.5, P = 0.001), HbA1c (34.3 ± 0.6 vs. 38.0 ± 4.5, P = 0.0002), triglycerides (mmol/l) (1.3 ± 0.6 vs. 1.6 ± 0.8, P = 0.005) and low-density lipoprotein cholesterol (mmol/l) (2.7 ± 0.7 vs. 3.1 ± 0.9, P = 0.02) and an increase in high-density lipoprotein cholesterol (mmol/l) (1.2 ± 0.3 vs. 1.04 ± 0.2, P = 0.002). There was a significant improvement in NSP (1.6 ± 2.7 vs. 4.3 ± 5.7, P = 0.004), neuropathy disability score (0.3 ± 0.9 vs. 1.3 ± 2.0, P = 0.03), CNFD (28.2 ± 4.4 vs. 25.6 ± 5.3, P = 0.03), CNBD (64.7 ± 26.1 vs. 56.9 ± 27.5, P = 0.04) and CNFL (20.4 ± 1.2 vs. 17.9 ± 4.1, P = 0.02), but no change in cold and warm threshold, VPT, DB-HRV or nerve conduction velocity and amplitude. Increase in CNFD correlated with a decrease in triglycerides (r = -0.45, P = 0.04). CONCLUSION: Obese subjects have evidence of neuropathy, and bariatric surgery leads to an improvement in weight, HbA1c, lipids, neuropathic symptoms and deficits and small nerve fibre regeneration without a change in quantitative sensory testing, autonomic function or neurophysiology.
INTRODUCTION: Subjects with obesity have metabolic risk factors for nerve fibre damage. Because bariatric surgery improves these risk factors we have assessed whether this can ameliorate nerve fibre damage. METHODS: Twenty-six obese subjects without diabetes (age: 46.23 ± 8.6, BMI: 48.7 ± 1.5, HbA1c: 38.0 ± 4.5) and 20 controls (age: 48.3 ± 6.2, BMI: 26.8 ± 4.2, HbA1c: 39.1 ± 2.6) underwent detailed assessment of neuropathy at baseline and 12 months after bariatric surgery. RESULTS: Obese subjects had normal peroneal (45.9 ± 5.5 vs. 48.1 ± 4.5, P = 0.1) and sural (46.9 ± 7.6 vs. 47.9 ± 10.6, P = 0.1) nerve conduction velocity, but a significantly higher neuropathy symptom profile (NSP) (4.3 ± 5.7 vs. 0.3 ± 0.6, P = 0.001), vibration perception threshold (VPT) (V) (10.2 ± 6.8 vs. 4.8 ± 2.7, P < 0.0001), warm threshold (C°) (40.4 ± 3.5 vs. 37.2 ± 1.8, P = 0.003) and lower peroneal (3.8 ± 2.2 vs. 4.9 ± 2.2, P = 0.02) and sural (8.9 ± 5.8 vs. 15.2 ± 8.5, P < 0.0001) nerve amplitude, deep breathing-heart rate variability (DB-HRV) (beats/min) (21.7 ± 4.1 vs. 30.1 ± 14, P = 0.001), corneal nerve fibre density (CNFD) (n/mm2) (25.6 ± 5.3 vs. 32.0 ± 3.1, P < 0.0001), corneal nerve branch density (CNBD) (n/mm2) (56.9 ± 27.5 vs. 111.4 ± 30.7, P < 0.0001) and corneal nerve fibre length (CNFL) (mm/mm2) (17.9 ± 4.1 vs. 29.8 ± 4.9, P < 0.0001) compared to controls at baseline. In control subjects there was no change in neuropathy measures over 12 months. However, 12 months after bariatric surgery there was a significant reduction in BMI (33.7 ± 1.7 vs. 48.7 ± 1.5, P = 0.001), HbA1c (34.3 ± 0.6 vs. 38.0 ± 4.5, P = 0.0002), triglycerides (mmol/l) (1.3 ± 0.6 vs. 1.6 ± 0.8, P = 0.005) and low-density lipoprotein cholesterol (mmol/l) (2.7 ± 0.7 vs. 3.1 ± 0.9, P = 0.02) and an increase in high-density lipoprotein cholesterol (mmol/l) (1.2 ± 0.3 vs. 1.04 ± 0.2, P = 0.002). There was a significant improvement in NSP (1.6 ± 2.7 vs. 4.3 ± 5.7, P = 0.004), neuropathy disability score (0.3 ± 0.9 vs. 1.3 ± 2.0, P = 0.03), CNFD (28.2 ± 4.4 vs. 25.6 ± 5.3, P = 0.03), CNBD (64.7 ± 26.1 vs. 56.9 ± 27.5, P = 0.04) and CNFL (20.4 ± 1.2 vs. 17.9 ± 4.1, P = 0.02), but no change in cold and warm threshold, VPT, DB-HRV or nerve conduction velocity and amplitude. Increase in CNFD correlated with a decrease in triglycerides (r = -0.45, P = 0.04). CONCLUSION: Obese subjects have evidence of neuropathy, and bariatric surgery leads to an improvement in weight, HbA1c, lipids, neuropathic symptoms and deficits and small nerve fibre regeneration without a change in quantitative sensory testing, autonomic function or neurophysiology.
Authors: Sabrina Schlesinger; Christian Herder; Julia M Kannenberg; Cornelia Huth; Maren Carstensen-Kirberg; Wolfgang Rathmann; Gidon J Bönhof; Wolfgang Koenig; Margit Heier; Annette Peters; Christa Meisinger; Michael Roden; Barbara Thorand; Dan Ziegler Journal: Diabetes Care Date: 2018-12-06 Impact factor: 19.112
Authors: Dan Ziegler; Nikolaos Papanas; Andrey Zhivov; Stephan Allgeier; Karsten Winter; Iris Ziegler; Jutta Brüggemann; Alexander Strom; Sabine Peschel; Bernd Köhler; Oliver Stachs; Rudolf F Guthoff; Michael Roden Journal: Diabetes Date: 2014-02-26 Impact factor: 9.461
Authors: Lawrence Coppey; Eric Davidson; Hanna Shevalye; Michael E Torres; Mark A Yorek Journal: Diabetes Metab Syndr Obes Date: 2018-04-09 Impact factor: 3.168
Authors: Dan Ziegler; Karsten Winter; Alexander Strom; Andrey Zhivov; Stephan Allgeier; Nikolaos Papanas; Iris Ziegler; Jutta Brüggemann; Bernd Ringel; Sabine Peschel; Bernd Köhler; Oliver Stachs; Rudolf F Guthoff; Michael Roden Journal: PLoS One Date: 2017-03-15 Impact factor: 3.240
Authors: Omar Asghar; Ioannis N Petropoulos; Uazman Alam; Wendy Jones; Maria Jeziorska; Andrew Marshall; Georgios Ponirakis; Hassan Fadavi; Andrew J M Boulton; Mitra Tavakoli; Rayaz A Malik Journal: Diabetes Care Date: 2014-06-26 Impact factor: 19.112
Authors: Jeremy Chung Bo Chiang; Ria Arnold; Roshan Dhanapalaratnam; Maria Markoulli; Arun V Krishnan Journal: Pharmaceuticals (Basel) Date: 2022-05-15
Authors: Georgios Ponirakis; Ibrahim Al-Janahi; Einas Elgassim; Hoda Gad; Ioannis N Petropoulos; Adnan Khan; Hamda Ali; Mashhood A Siddique; Wajiha Gul; Maryam Ferdousi; Alise Kalteniece; Fatima Fs Mohamed; Lina Hm Ahmed; Youssra Dakroury; Abeer Mm El Shewehy; Abdulrahman Al-Mohamedi; Fatema AlMarri; Moayad Homssi; Murtaza Qazi; Nebras H Hadid; Fatima Al-Khayat; Ziyad R Mahfoud; Shazli Azmi; Uazman Alam; Mahmoud A Zirie; Yousuf Al-Ansari; Amin Jayyousi; Alan S Rigby; Eric S Kilpatrick; Stephen L Atkin; Rayaz A Malik Journal: J Diabetes Investig Date: 2022-06-20 Impact factor: 3.681
Authors: Piotr Bienias; Zuzanna Rymarczyk; Justyna Domienik-Karłowicz; Wojciech Lisik; Piotr Sobieraj; Piotr Pruszczyk; Michał Ciurzyński Journal: J Clin Med Date: 2021-05-15 Impact factor: 4.241